Terbinafine

Generic Name
Terbinafine
Brand Names
Lamisil, Silka Cream
Drug Type
Small Molecule
Chemical Formula
C21H25N
CAS Number
91161-71-6
Unique Ingredient Identifier
G7RIW8S0XP
Background

Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wal...

Indication

Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by Trichophyton species, Microsporum canis, Epidermophyton floccosum, and Tinea species. Terbinafine hydrochloride also treats yeast infections of the skin caused by Candida species and Malassezia furfur.

Associated Conditions
Onychomycosis, Pityriasis versicolor, Sporotrichosis, Tinea Capitis, Tinea Corporis, Tinea Cruris, Tinea Pedis, Cutaneous candidiasis, Severe Tinea Corporis, Severe Tinea Cruris, Severe Tinea Pedis
Associated Therapies
-

Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis

Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-05-06
Last Posted Date
2024-05-06
Lead Sponsor
Assiut University
Target Recruit Count
30
Registration Number
NCT06400056

From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients

First Posted Date
2024-03-06
Last Posted Date
2024-03-06
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
36
Registration Number
NCT06295328
Locations
🇳🇱

Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands

Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-10-13
Last Posted Date
2022-10-19
Lead Sponsor
Combined Military Hospital Abbottabad
Target Recruit Count
100
Registration Number
NCT05578950
Locations
🇵🇰

Cmh Abbottabad, Abbottābād, Khyber Pakhtunkhwa, Pakistan

Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis

First Posted Date
2018-03-20
Last Posted Date
2018-05-01
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
100
Registration Number
NCT03471455

Antifungal Drugs in Treatment of Onychomycosis

First Posted Date
2017-05-31
Last Posted Date
2017-05-31
Lead Sponsor
Assiut University
Target Recruit Count
60
Registration Number
NCT03171584

Three-Arm Trial of Novel Treatment for Tinea Pedis

First Posted Date
2017-05-02
Last Posted Date
2017-10-06
Lead Sponsor
South End Skin Care
Target Recruit Count
90
Registration Number
NCT03135912
Locations
🇺🇸

Kuchnir Dermatology & Dermatologic Surgery, Milford, Massachusetts, United States

Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis

First Posted Date
2015-11-17
Last Posted Date
2021-02-10
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
75
Registration Number
NCT02606032
Locations
🇨🇦

Hamilton Health Sciences / McMaster University, Hamilton, Ontario, Canada

Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis

First Posted Date
2013-05-10
Last Posted Date
2015-11-30
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
129
Registration Number
NCT01851590
Locations
🇫🇮

Vääksyn Lääkärikeskus, Vääksy, Finland

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-12-02
Last Posted Date
2012-10-19
Lead Sponsor
Nitric BioTherapeutics, Inc
Target Recruit Count
25
Registration Number
NCT01484145
Locations
🇺🇸

Cetero Research, San Antonio, Texas, United States

Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-09-13
Last Posted Date
2013-12-27
Lead Sponsor
Novartis
Target Recruit Count
290
Registration Number
NCT01433107
Locations
🇨🇳

The Second Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China

🇨🇳

Chinese Academy of Medical Sciences, Jiangsu, China

🇨🇳

Peking University First Hospital, Beijing, China

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath